Sacituzumab Govitecan in Advanced Urothelial Cancer After ICI Therapy - The ASCO Post
In TROPHY-U-01 study, sacituzumab govitecan showed activity in cisplatin-ineligible patients with advanced urothelial cancer post-ICI therapy, with 32% objective response rate and manageable toxicity. Further evaluation is warranted.
Reference News
Sacituzumab Govitecan in Advanced Urothelial Cancer After ICI Therapy - The ASCO Post
In TROPHY-U-01 study, sacituzumab govitecan showed activity in cisplatin-ineligible patients with advanced urothelial cancer post-ICI therapy, with 32% objective response rate and manageable toxicity. Further evaluation is warranted.